



FROM BILLIONS TO MILLIONS

VIDEO TRANSCRIPT

Faster innovation. Greater R&D productivity.

In Life Sciences, innovating at speed has become the number one driver of success. And the Biopharma industry has proven that new treatments can be brought to patients in need at a staggering pace.

Yet, price pressures continue to strain the healthcare ecosystem, making it more difficult to bring affordable treatments to market.

How do you overcome this challenge, accelerate innovation and outpace the competition?

The way companies operate in R&D plays a pivotal role. It's time to shift strategy and re-imagine R&D productivity with digitally-powered, patient-centric design.

Learn how to drive faster innovation and bring discovery and development costs down - from billions to millions.

Accenture Life Sciences has developed a model to positively disrupt the current R&D productivity equation. It's about capturing value through the convergence of data, advanced analytics, technology, and human ingenuity.

It comes together in "three strategic plays": A New Science portfolio, digital and data-led research, and faster, smarter development.

Combined with coordinated investments across specific technologies and enabling capabilities, they have a substantial impact on costs and time to market.

Realizing the value from this R&D transformation, our model suggests savings of 1.2 to 1.7 billion dollars per successful treatment brought to market; and additional revenue opportunities of 150 to 450 million dollars.

By reducing the cost of failure, while significantly improving the PTRS and time to market, our clients are transforming their R&D productivity.

Learn more about how Accenture Life Sciences is helping clients innovate faster and smarter, and drive R&D costs down from billions to millions.

Copyright © 2019 Accenture
All rights reserved.

Accenture, its logo, and High Performance Delivered are trademarks of Accenture.